Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Pelacarsen in Subjects with Normal and Impaired Renal Function
NCT03506854Phase 1Completed
- Sponsor
- Akcea Therapeutics
- Start
- Mar 2018
- Primary completion
- Oct 2018
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 2
01
Overview
Phase 1, open-label trial of pelacarsen in Hyperlipoproteinemia a (2 arms), sponsored by Akcea Therapeutics. Primary endpoint: Effect of ISIS 681257 on Pharmacokinetics at Day 31. Started Mar 2018; status: completed.
02
Drugs
pelacarsen
03
Conditions
Hyperlipoproteinemia a
Beyond the preview
Go deeper on NCT03506854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03506854.